Shots:
- Harbour BioMed has entered into a long-term strategic collaboration with Yantai Lannacheng Biotechnology to jointly advance the development of next-generation RDCs
- Collaboration will combine Harbour’s fully human antibody discovery capabilities via its Harbour Mice platform with Lannacheng’s radiopharmaceutical R&D & commercialization strengths
- Harbour Mice platform provides fully human mAbs in both conventional & heavy chain-only formats to enhance targeted efficiency & safety, while Lannacheng contributes integrated radiopharmaceutical platforms, isotope supply, & GMP manufacturing to accelerate pipeline development
Ref: PR newswire | Image: Harbour Biomed | Press Release
Related News: Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
